VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

L. infantum H1 protein vaccine L. infantum HASPB1 protein vaccine
Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0011350
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: L. infantum histone H1
  • H1 gene engineering:
    • Type: Recombinant protein preparation
    • Description: The histone H1 and HASPB1 proteins were purified from endotoxins under pyrogenic free conditions in 1× PBS on a Superose 12 column (Amersham Biosciences) (Moreno et al., 2007).
    • Detailed Gene Information: Click Here.
  • Adjuvant: Montanide ISA 720
    • VO ID: VO_0001268
    • Description: Montanide™ ISA 720 (70% formulation, according to manufacturer's instructions, SEPPIC)
  • Immunization Route: Intradermal injection (i.d.)
  • Vaccine Ontology ID: VO_0011351
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: L. infantum HASPB1
  • HASPB1 gene engineering:
    • Type: Recombinant protein preparation
    • Description: The L. infantum histone H1 was cloned into the pGEX-KG vector (Amersham Biosciences), expressed in Escherichia coli and purified using GST affinity resin (Amersham Biosciences) (Moreno et al., 2007).
    • Detailed Gene Information: Click Here.
  • Adjuvant: Montanide ISA 720
    • VO ID: VO_0001268
    • Description: Montanide™ ISA 720 (70% formulation, according to manufacturer's instructions, SEPPIC)
  • Immunization Route: Intradermal injection (i.d.)
Host Response Host Response

Dog Response

  • Host Strain: Beagle
  • Vaccination Protocol: Dogs received three intradermal doses (dorsum; 1 ml/dose) of each vaccine formulation for a period of 3 months. On day 0, dogs from group HASPB1 and group H1 received 100 μg of HASPB1 or histone H1 protein. On days 30 and 60 the dogs received 45 μg of either protein. Dogs in group HASPB1 + H1 received a cocktail of histone H1 and HASPB1 (100 μg each) at day 0, and 45 μg of each protein on days 30 and 60. The adjuvant used for dogs in groups HASPB1, H1 and HASPB1 + H1 was Montanide™ ISA 720 (70% formulation, according to manufacturer's instructions, SEPPIC), given on days 0 and 30. The final immunization on day 60 for groups HASPB1, H1, and HASPB1 + H1 was prepared in the absence of adjuvant to avoid side effects observed following the second dose (Moreno et al., 2007).
  • Challenge Protocol: Forty-five days following the final immunization, all dogs were infected intravenously with 1 × 108 virulent L. infantum promastigotes (Moreno et al., 2007).
  • Efficacy: Following infection with L. infantum promastigotes, five out of eight beagle dogs immunized with H1 Montanide remained free of clinical signs, compared to two out of eight dogs in the control group. The results demonstrate that H1 antigens with Montanide were able to induce partial protection against canine leishmaniasis, even under extreme experimental challenge conditions (Moreno et al., 2007).

Dog Response

  • Host Strain: Beagle
  • Vaccination Protocol: Dogs received three intradermal doses (dorsum; 1 ml/dose) of each vaccine formulation for a period of 3 months. On day 0, dogs from group HASPB1 and group H1 received 100 μg of HASPB1 or histone H1 protein. On days 30 and 60 the dogs received 45 μg of either protein. Dogs in group HASPB1 + H1 received a cocktail of histone H1 and HASPB1 (100 μg each) at day 0, and 45 μg of each protein on days 30 and 60. The adjuvant used for dogs in groups HASPB1, H1 and HASPB1 + H1 was Montanide™ ISA 720 (70% formulation, according to manufacturer's instructions, SEPPIC), given on days 0 and 30. The final immunization on day 60 for groups HASPB1, H1, and HASPB1 + H1 was prepared in the absence of adjuvant to avoid side effects observed following the second dose (Moreno et al., 2007).
  • Challenge Protocol: Forty-five days following the final immunization, all dogs were infected intravenously with 1 × 108 virulent L. infantum promastigotes (Moreno et al., 2007).
  • Efficacy: Following infection with L. infantum promastigotes, four out of eight beagle dogs immunized with HASPB1 Montanide remained free of clinical signs, compared to two out of eight dogs in the control group. The results demonstrate that HASPB1 antigens with Montanide were able to induce partial protection against canine leishmaniasis, even under extreme experimental challenge conditions (Moreno et al., 2007).
References References
Moreno et al., 2007: Moreno J, Nieto J, Masina S, CaƱavate C, Cruz I, Chicharro C, Carrillo E, Napp S, Reymond C, Kaye PM, Smith DF, Fasel N, Alvar J. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine. 2007; 25(29); 5290-5300. [PubMed: 17576026].
Moreno et al., 2007: Moreno J, Nieto J, Masina S, CaƱavate C, Cruz I, Chicharro C, Carrillo E, Napp S, Reymond C, Kaye PM, Smith DF, Fasel N, Alvar J. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine. 2007; 25(29); 5290-5300. [PubMed: 17576026].